Zurcher Kantonalbank Zurich Cantonalbank Grows Position in Illumina, Inc. (NASDAQ:ILMN)

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Illumina, Inc. (NASDAQ:ILMN) by 30.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 81,267 shares of the life sciences company’s stock after acquiring an additional 19,202 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Illumina were worth $11,316,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Acadian Asset Management LLC grew its stake in Illumina by 312.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock worth $702,000 after buying an additional 1,525 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Illumina by 3.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock worth $82,853,000 after buying an additional 7,114 shares during the last quarter. Dakota Wealth Management grew its stake in Illumina by 13.8% during the 1st quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock worth $288,000 after buying an additional 100 shares during the last quarter. Sequoia Financial Advisors LLC grew its stake in Illumina by 16.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock worth $281,000 after buying an additional 116 shares during the last quarter. Finally, Baird Financial Group Inc. grew its stake in Illumina by 10.2% during the 1st quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock worth $17,108,000 after buying an additional 4,548 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $253.00 price target on shares of Illumina in a research note on Tuesday, April 9th. StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, April 10th. OTR Global reissued a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Finally, Barclays increased their price target on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $167.70.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $117.43 on Friday. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $229.58. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $133.37 and a 200-day simple moving average of $127.94.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. Illumina’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.14 earnings per share. On average, research analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen acquired 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.17% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.